Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?

Abstract

INTRODUCTION Systemic lupus erythematosus (SLE) is a diverse autoimmune disease affecting many different organ systems. Although disease manifestations are varied across the lupus population, the widespread presence of autoantibodies indicates that SLE immunopathology involves B-cell dysregulation. Belimumab, a human anti-B-cell activating factor (BLyS… (More)
DOI: 10.1517/14712598.2014.884065

Topics

  • Presentations referencing similar topics